The study of 33,000 HIV patients, which was done to determine the short and long term risk of taking AIDS drugs, revealed that patients taking Ziagen (a GlaxoSmithKline drug) and Videx (a Bristol-Myers Squibb drug) were at increased risk of heart health problems when compared to other types of treatment.
The FDA says that the results that will be obtained from their investigation may lead to labeling changes for both drugs.
FDA said in a notice posted on its website that until their evaluation is complete, health care providers should evaluate the potential risks and benefits of each HIV drugs their patients are taking.
GSK and Bristol said their companies had their own data on the drugs, and both said they found no increased risk of heart attack.
